Description

This tablet combines Ainuovirine (a novel NNRTI), Lamivudine (3TC), and Tenofovir Disoproxil Fumarate (TDF) in a fixed?dose formulation known as Compound ACC007. The regimen shows non?inferior efficacy versus efavirenz-based protocols with improved lipid profile and safety in clinical trials. In research, these tablets facilitate modeling of HIV?1 replication suppression, antiviral resistance pathways, pharmacokinetics, and pre?exposure prophylaxis. Approved in China on December 30, 2022. Supplied 30 tablets per box. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Ainuovirine inhibits HIV?1 reverse transcriptase (RT) as a novel NNRTI, while lamivudine and tenofovir act as nucleoside and nucleotide RT inhibitors. The combination delivers potent antiviral suppression, demonstrates favorable lipid and safety profiles compared to efavirenz regimens, and is widely used to model antiretroviral efficacy, resistance development, PK/PD interactions, and HIV?1 research protocols.

Side Effects (For Reference Only in Research Models)

Clinical trial analogs of ANV/3TC/TDF tablets reported fewer dyslipidemia events, lower rates of liver enzyme elevation and rash, with overall favorable tolerability compared to EFV-based regimens. Common reported effects include mild dizziness and lipid changes; severe adverse events were limited in clinical studies up to 96 weeks.

Disclaimer

Ainuovirine, Lamivudine & Tenofovir Disoproxil Fumarate Tablets are strictly intended for laboratory research use only. Not for human or veterinary therapeutic, prophylactic, or diagnostic use.